Gensetix, Inc. v. Baylor College of Medicine ( 2020 )


Menu:
  • Case: 19-1424    Document: 77     Page: 1   Filed: 07/24/2020
    United States Court of Appeals
    for the Federal Circuit
    ______________________
    GENSETIX, INC.,
    Plaintiff-Appellant
    v.
    THE BOARD OF REGENTS OF THE UNIVERSITY
    OF TEXAS SYSTEM,
    Plaintiff-Appellee
    v.
    BAYLOR COLLEGE OF MEDICINE, DIAKONOS
    RESEARCH LTD, WILLIAM K. DECKER,
    Defendants-Appellees
    ______________________
    2019-1424
    ______________________
    Appeal from the United States District Court for the
    Southern District of Texas in No. 4:17-cv-01025, Judge An-
    drew S. Hanen.
    ______________________
    Decided: July 24, 2020
    ______________________
    PAUL SKIERMONT, Skiermont Derby LLP, Dallas, TX,
    argued for plaintiff-appellant. Also represented by SARAH
    ELIZABETH SPIRES; MIEKE K. MALMBERG, Los Angeles, CA;
    CHRISTOPHER MICHAEL HODGE, Oracle Corp., Irving, TX;
    IMRON T. ALY, Schiff Hardin, Chicago, IL.
    Case: 19-1424      Document: 77    Page: 2   Filed: 07/24/2020
    2               GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    PETER E. MIMS, Vinson & Elkins LLP, Houston, TX, ar-
    gued for plaintiff-appellee. Also represented by OLIN RAY
    HEBERT, III, Austin, TX.
    MICHAEL HAWES, Baker Botts, LLP, Houston, TX, ar-
    gued for defendants-appellees Baylor College of Medicine,
    Diakonos Research Ltd. Defendant-appellee Baylor Col-
    lege of Medicine also represented by PAUL R. MORICO.
    GORDON ARNOLD, Arnold, Knobloch & Saunders,
    L.L.P., Houston, TX, for defendant-appellee Diakonos Re-
    search Ltd.
    MURRAY JULES FOGLER, Fogler Brar O'Neil and Gray
    LLP, Houston, TX, for defendant-appellee William K.
    Decker.
    ______________________
    Before NEWMAN, O’MALLEY, and TARANTO, Circuit Judges.
    Opinion for the court filed by Circuit Judge O’MALLEY.
    Opinion concurring in part and dissenting in part filed by
    Circuit Judge NEWMAN.
    Opinion concurring in part and dissenting in part filed by
    Circuit Judge TARANTO.
    O’MALLEY, Circuit Judge.
    This case involves the interplay of state sovereign im-
    munity under the Eleventh Amendment and required join-
    der of parties under Rule 19 of the Federal Rules of Civil
    Procedure. Gensetix, Inc. (“Gensetix”) exclusively licensed
    U.S. Patent Nos. 8,728,806 and 9,333,248 from the Univer-
    sity of Texas (“UT”), an arm of the state of Texas. Gensetix
    then sued Baylor College of Medicine, Diakonos Research
    Ltd., and William K. Decker (collectively, “Baylor”) for in-
    fringement of the patents-in-suit, naming UT as an
    Case: 19-1424     Document: 77      Page: 3    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                 3
    involuntary plaintiff pursuant to Rule 19(a). The District
    Court for the Southern District of Texas determined that
    the Eleventh Amendment barred joinder of UT as an invol-
    untary plaintiff. Gensetix, Inc. v. Baylor Coll. of Med., 
    354 F. Supp. 3d 759
    , 766 (S.D. Tex. 2018). The court also con-
    cluded that, under Rule 19(b), the suit could not proceed in
    UT’s absence.
    Id. at 773–74.
    Accordingly, the court dis-
    missed the suit. This appeal followed. For the reasons
    stated below, we affirm-in-part, reverse-in-part, and re-
    mand.
    I. BACKGROUND
    The patents-in-suit are directed to methods of modify-
    ing a patient’s immune system to kill cancer cells. Decker,
    the named inventor of the patents-in-suit, developed his in-
    vention during his employment at the University of Texas
    MD Anderson Cancer Center. Pursuant to the terms of
    Decker’s employment agreement, the patents-in-suit were
    assigned to UT. 1 In September 2008, UT granted an exclu-
    sive license in the patents-in-suit to Alex Mirrow, a third
    party not relevant to this suit. In January 2014, Mirrow
    assigned his rights in the exclusive license to Gensetix. UT
    confirmed Mirrow’s assignment of the exclusive license to
    Gensetix in a June 2014 amendment.
    The license agreement provides that, Gensetix, at its
    own expense, must enforce any patent “covered by the li-
    cense and is entitled to retain recovery from such enforce-
    ment.” 
    Gensetix, 354 F. Supp. 3d at 769
    . UT retained a
    secondary right to sue if Gensetix fails to file suit against a
    substantial infringer within six months of knowledge of
    1    According to the complaint, Decker left the Univer-
    sity of Texas MD Anderson Cancer Center around 2011 and
    joined the faculty at Baylor College of Medicine. J.A. 119.
    Neither Decker nor Baylor College of Medicine have li-
    censed the patents-in-suit from UT or Gensetix.
    Case: 19-1424     Document: 77     Page: 4    Filed: 07/24/2020
    4              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    infringement.
    Id. The parties
    agreed to fully cooperate
    with each other in any infringement suit. And, the parties
    agreed that nothing in the agreement shall be deemed a
    waiver by UT of its sovereign immunity.
    Id. at 772.
           In April 2017, Gensetix filed this suit against Baylor,
    alleging infringement of the patents-in-suit. Gensetix
    noted that, before filing its complaint, it requested that UT
    join as a co-plaintiff, but UT declined. Gensetix therefore
    named UT as an involuntary plaintiff pursuant to
    Rule 19(a). J.A. 115–16. In its complaint, Gensetix alleged
    that Decker “continued and continues to use technology
    that infringes one or more claims of the [p]atents-in-[s]uit
    . . . as part of his work at” Baylor. J.A. 119. Gensetix also
    alleged that in 2013 and 2014, Decker published content
    while at Baylor that “gives Gensetix reason to believe” that
    Decker has practiced methods infringing at least claim 1 of
    each of the patents-in-suit.
    Id. According to
    the complaint,
    in May 2016, Baylor filed two patent applications, naming
    Decker as an inventor, which rely on the methods claimed
    in the patents-in-suit. J.A. 127.
    UT filed a motion to dismiss pursuant to Rule 12(b)(1),
    seeking to dismiss itself from the lawsuit. UT argued that
    it is a sovereign state entity under Texas law and that, un-
    der the Eleventh Amendment, the district court had no
    subject matter jurisdiction over UT. 2 It argued that,
    2    As the district court noted, the Eleventh Amend-
    ment “confers waivable immunity upon sovereign entities
    ‘rather than a nonwaivable limit on the Federal Judiciary’s
    subject-matter jurisdiction.’’’ 
    Gensetix, 354 F. Supp. 3d at 764
    (quoting Idaho v. Coeur d’Alene Tribe of Idaho, 
    521 U.S. 261
    , 267 (1997). The court correctly concluded that
    the Eleventh Amendment does not necessarily deprive fed-
    eral courts of subject matter jurisdiction, rather, the “issue
    in this case is whether the Eleventh Amendment prevents
    Case: 19-1424    Document: 77      Page: 5    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE               5
    pursuant to the license agreement, it had not waived its
    sovereign immunity, nor did it have the authority to do so
    because such authority lies only with the Texas Legisla-
    ture.
    Baylor argued that: (1) UT is a necessary party be-
    cause it owns the patents-in-suit and transferred less than
    all substantial patent rights to Gensetix; (2) UT cannot be
    joined as an involuntary plaintiff because, as an entity of
    the State of Texas, it is entitled to Eleventh Amendment
    sovereign immunity; and (3) the Rule 19(b) factors weigh
    in favor of dismissing the suit, rather than proceeding in
    UT’s absence.
    The district court granted UT’s motion to dismiss. It
    held that “[t]he purpose of the Eleventh Amendment is to
    prevent states from being compelled to litigate.” 
    Gensetix, 354 F. Supp. 3d at 766
    (internal quotation marks omitted).
    It found that, while “there [were] currently no claims
    against UT, requiring joinder would, in effect, force UT to
    pursue claims against its will.”
    Id. Accordingly, the
    court
    held that, because “UT did not waive its immunity, initiate
    [the] suit, or agree to participate in [the] litigation,” the
    Eleventh Amendment prohibited involuntary joinder.
    Id. As to
    whether the infringement suit could proceed in
    UT’s absence, the court held that UT was a “necessary”
    party under Rule 19(a) because it retained substantial
    rights in the patents-in-suit. 3 Analyzing the applicable
    UT from being joined as an involuntary plaintiff in a patent
    suit.”
    Id. 3 Rule
    19 no longer uses the term “necessary party;”
    the more modern term is “required party.” See Republic of
    the Phil. v. Pimentel, 
    553 U.S. 851
    , 855–56 (2008). The
    Rule also no longer uses the term “indispensable.”
    Id. These changes
    were intended to be stylistic only. See Fed.
    Case: 19-1424     Document: 77     Page: 6    Filed: 07/24/2020
    6              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    Rule 19(b) factors, the district court concluded that UT was
    an “indispensable” party, and that the suit could not pro-
    ceed in its absence.
    Id. at 773–74.
    Accordingly, the court
    dismissed the case. Gensetix timely appealed. We have
    jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).
    II. DISCUSSION
    On appeal, Gensetix argues that the district court
    (1) erred in holding that sovereign immunity bars coercive
    joinder of UT pursuant to Rule 19(a); and (2) abused its
    discretion in determining that, under Rule 19(b), the in-
    fringement suit should be dismissed rather than proceed in
    UT’s absence. 4 We address each argument in turn.
    A. Sovereign Immunity Bars Rule 19(a)(2) Joinder
    Rule 19(a)(2) requires a court to order a required plain-
    tiff “who refuses to join as a plaintiff” to “be made either a
    defendant or, in a proper case, an involuntary plaintiff.”
    Fed. R. Civ. P. 19(a)(2). The Eleventh Amendment pro-
    vides, however, that “[t]he Judicial power of the United
    States shall not be construed to extend to any suit in law
    or equity, commenced or prosecuted against one of the
    United States by Citizens of another State, or by Citizens
    or Subjects of any Foreign State.” U.S. Const. amend. XI.
    Although the procedural issue of joinder under Rule 19 is
    not unique to patent law, and we thus review its applica-
    tion under the law of the regional circuit, to the extent the
    district court assessed the interplay between Rule 19 and
    the Eleventh Amendment, we review that question using
    the law of our circuit. Regents of Univ. of N.M. v. Knight,
    
    321 F.3d 1111
    , 1124 (Fed. Cir. 2003). We therefore apply
    R. Civ. P. 19 advisory committee’s note to 2007 amend-
    ment.
    4   Gensetix does not challenge the district court’s con-
    clusion that, pursuant to the license agreement, UT did not
    transfer all substantial rights in the patents to Gensetix.
    Case: 19-1424     Document: 77     Page: 7    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                7
    our law and review the district court’s decision on Eleventh
    Amendment immunity de novo.
    Id. On appeal,
    Gensetix argues that sovereign immunity
    does not preclude coercive joinder of a sovereign under
    Rule 19(a)(2). In Gensetix’s view, the Eleventh Amend-
    ment bars suits brought by private citizens against the
    state, which is not the case here. Appellant’s Br. 41–42
    (citing Regents of the Univ. of Cal. v. Eli Lilly & Co.,
    
    119 F.3d 1559
    , 1564 (Fed. Cir. 1997) (“Regents of UC”)).
    Gensetix argues that, like Regents of UC, here, there are
    no claims or counterclaims against UT, thereby making
    sovereign immunity inapplicable.
    Id. at 43.
    Gensetix also
    contends that both the Supreme Court and our court have
    consistently held that a patentee who refuses to voluntarily
    join an infringement action initiated by its exclusive licen-
    see can nonetheless be joined as an involuntary plaintiff.
    Id. at 39–41
    (citing, e.g., Indep. Wireless Tel. Co. v. Radio
    Corp. of Am., 
    269 U.S. 459
    , 473 (1926), and Abbott Labs. v.
    Diamedix Corp., 
    47 F.3d 1128
    , 1133 (Fed. Cir. 1995)).
    UT responds that sovereign immunity protects it from
    private party litigation and this protection extends to join-
    der under Rule 19(a). According to UT, sovereign immun-
    ity “controls over the joinder process of Rule 19.” UT
    Br. 14. And, relying on the Supreme Court’s decision in
    
    Pimentel, 553 U.S. at 869
    , UT argues that, where there is
    a “potential for injury to the interests” of the absent sover-
    eign, the suit must be dismissed.
    Id. at 15.
          Like UT, Baylor argues that the Eleventh Amendment
    forbids the court from ordering UT to subject its property
    to federal court adjudication. Baylor Br. 16–17. According
    to Baylor, a state’s property rights cannot be limited or de-
    feated where the state neither brought a claim nor agreed
    to join the suit. And, like UT, Baylor points to the express
    language of Section 15.4 of the license agreement as indic-
    ative of UT’s refusal to waive sovereign immunity.
    Id. at Case:
    19-1424     Document: 77     Page: 8    Filed: 07/24/2020
    8              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    18–19. We agree that sovereign immunity is to be applied
    more broadly than the face of its text.
    Gensetix’s attempt to limit the Eleventh Amendment
    to its text—i.e., to cases “against” a state—is contrary to
    Supreme Court guidance. “[T]he sovereign immunity re-
    flected in (rather than created by) the Eleventh Amend-
    ment transcends the narrow text of the Amendment itself.”
    Coll. Sav. Bank v. Fla. Prepaid Postsecondary Ed. Expense
    Bd., 
    527 U.S. 666
    , 687 n.5 (1999). The Supreme Court has
    “understood the Eleventh Amendment to stand not so
    much for what it says, but for the presupposition . . . which
    it confirms.” Seminole Tribe of Fla. v. Fla., 
    517 U.S. 44
    , 54
    (1996) (quoting Blatchford v. Native Vill. of Noatak, 
    501 U.S. 775
    , 779 (1991)). Importantly, the Court has made
    clear that “[t]he Eleventh Amendment does not exist solely
    in order to prevent federal-court judgments that must be
    paid out of a State’s treasury; it also serves to avoid the
    indignity of subjecting a State to the coercive process of ju-
    dicial tribunals at the instance of private parties.” Semi-
    nole 
    Tribe, 517 U.S. at 58
    (citations and internal quotation
    marks omitted).
    Gensetix provides no basis for suggesting that these
    principles are inapplicable in cases where the state is
    joined as an involuntary plaintiff. Indeed, Gensetix’s reli-
    ance on our decision in Regents of UC is misplaced. Regents
    of UC involved a suit initiated by the University of Califor-
    nia in the Northern District of 
    California. 119 F.3d at 1559
    . In opposing transfer to the Southern District of
    Indiana, the university asserted that it only waived sover-
    eign immunity with respect to California federal courts and
    that the Eleventh Amendment barred transfer to a differ-
    ent district court.
    Id. at 1564.
    The defendant, Eli Lilly,
    argued that the Eleventh Amendment is inapplicable
    where a state asserts a claim and the suit involves no coun-
    terclaims against the state.
    Id. We agreed
    with Eli Lilly,
    explaining that the Supreme Court has “not construe[d]
    the Eleventh Amendment to apply to suits in which a state
    Case: 19-1424      Document: 77    Page: 9    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                9
    is solely a plaintiff, as UC is here.”
    Id. We further
    ex-
    plained that:
    [T]he Eleventh Amendment applies to suits
    “against” a state, not suits by a state. Thus, we
    need not determine whether UC waived its immun-
    ity only in California, because this case does not
    create an Eleventh Amendment jurisdictional is-
    sue concerning which the question of waiver even
    arises. This case only involves UC’s patent in-
    fringement claims and Lilly’s defenses; it does not
    involve any claim or counterclaim against UC that
    places UC in the position of a defendant. Accord-
    ingly, we conclude that the Eleventh Amendment
    does not deprive the Indiana district court of juris-
    diction in this case.
    Id. at 1564–65.
         Gensetix erroneously reads Regents of UC to broadly
    hold that Eleventh Amendment immunity is inapplicable
    in all cases where the state is a plaintiff (even if involun-
    tarily) and there are no counterclaims against the state.
    But Regents of UC did not create a rule whereby parties
    may drag a sovereign into the federal court system against
    its will simply because there is no claim “against” the sov-
    ereign. Instead, our holding in that case was predicated on
    the state voluntarily submitting itself to federal court ju-
    risdiction. Indeed, we recently explained that our interpre-
    tation of the Eleventh Amendment in Regents of UC was
    “guided by” the Supreme Court’s reasoning that:
    “[W]here a state voluntarily become[s] a party to a
    cause, and submits its rights for judicial determi-
    nation, it will be bound thereby, and cannot escape
    the result of its own voluntary act by invoking the
    prohibitions of the 11th Amendment.” Gunter v.
    Atl. Coast Line R.R. Co., 
    200 U.S. 273
    , 284 (1906).
    Moreover, [i]t would seem anomalous or incon-
    sistent for a State both (1) to invoke federal
    Case: 19-1424    Document: 77      Page: 10     Filed: 07/24/2020
    10             GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    jurisdiction, thereby contending that the “Judicial
    power of the United States” extends to the case at
    hand, and (2) to claim Eleventh Amendment im-
    munity, thereby denying that the “Judicial power
    of the United States” extends to the case at hand.
    Lapides v. Bd. of Regents of Univ. Sys. of Ga., 
    535 U.S. 613
    , 619 (2002).
    Regents of the Univ. of Tex. Sys. v. Bos. Sci. Corp., 
    936 F.3d 1365
    , 1376–77 (Fed. Cir. 2019) (alterations in origi-
    nal).
    We conclude that the key distinction between Regents
    of UC and the present case—that UT did not voluntarily
    invoke federal court jurisdiction—is dispositive. Unlike
    the sovereign in Regents of UC, UT did not attempt to avail
    itself of federal court jurisdiction, and, in fact, has repeat-
    edly made clear that it does not want to participate in this
    litigation. 5 It is immaterial that there are no claims
    against UT, or that UT is named an involuntary plaintiff
    rather than an involuntary defendant. The Eleventh
    Amendment serves to prevent “the indignity of subjecting
    a State to the coercive process of judicial tribunals” against
    its will. Seminole 
    Tribe, 517 U.S. at 58
    . Accordingly,
    Rule 19(a)(2) cannot be used to drag an unwilling UT into
    federal court.
    5   Gensetix argues that “numerous appellate courts
    have confirmed” its reading of Regents of UC. Appellant’s
    Br. 43–44 (citing, e.g., California v. Atl. Richfield Co.,
    
    488 F.3d 112
    (2d Cir. 2007); Oklahoma ex rel. Edmondson
    v. Magnolia Marine Transp. Co., 
    359 F.3d 1237
    (10th Cir.
    2004)). But, as UT correctly points out, every case Gensetix
    relies on in support of this argument involves litigation in-
    itiated by a state as plaintiff, and a subsequent assertion of
    sovereign immunity to prevent removal. UT Br. 23–24.
    Case: 19-1424    Document: 77      Page: 11    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE               11
    Gensetix fares no better in its attempt to distinguish
    the other cases relied upon by the district court in reaching
    the same conclusion. For example, in Thomas v. Bearings
    Corp., 
    50 F.3d 502
    (8th Cir. 1995), the Eighth Circuit for-
    bade involuntary joinder of a state agency in a lawsuit by
    city residents against a company that had allegedly con-
    taminated their drinking water. The court held that the
    “Eleventh Amendment provides immunity from suit, not
    merely immunity from liability . . . . It may be circum-
    vented by waiver, abrogation, or a suit against state offi-
    cials, but federal courts cannot simply deem a state’s
    Eleventh Amendment defense inapplicable.”
    Id. at 506.
     The Eighth Circuit specifically noted that the Eleventh
    Amendment precludes involuntary joinder even if it in-
    volves later realignment of the state agency as a plaintiff.
    Id. at 502,
    504 n.5. Gensetix argues that, in Thomas, the
    Eighth Circuit was concerned with subjecting the state
    agency to premature litigation, “strik[ing] at the very heart
    of the Eleventh Amendment by undermining the state’s as-
    serted autonomy in decision-making.” Appellant’s Br.
    44–45 (citations omitted). In Gensetix’s view, here, joining
    UT as an involuntary plaintiff does not undermine the
    state’s autonomy. But forcing UT to litigate against its will
    does exactly that.
    Gensetix also relies on Independent Wireless, 
    269 U.S. 459
    (1926), and Abbott Laboratories, 
    47 F.3d 1128
     (Fed. Cir. 1995), to argue that “equity and justice” require
    joinder of UT. See Appellant’s Br. 39–40. In Gensetix’s
    view, UT voluntarily granted an exclusive license to Gen-
    setix and this license includes “an implied obligation” to the
    use of UT’s name. Appellant’s Br. 40 (citing Indep. Wire-
    
    less, 269 U.S. at 469
    ). Although Gensetix acknowledges
    that UT did not waive sovereign immunity, it nonetheless
    argues that UT willingly entered into the license agree-
    ment and must now abide by its terms. We disagree.
    When it comes to suits between private parties, Gen-
    setix is correct that a patentee who refuses to voluntarily
    Case: 19-1424     Document: 77      Page: 12     Filed: 07/24/2020
    12             GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    join an infringement action initiated by its exclusive licen-
    see can ordinarily be joined as an involuntary plaintiff un-
    der Rule 19(a). See, e.g., Indep. Wireless, 
    269 U.S. 459
     (1926); Lone Star Silicon Innovations LLC v. Nanya Tech.
    Corp., 
    925 F.3d 1225
    , 1237 (Fed. Cir. 2019) (collecting
    cases). But we refuse to extend that principle to this case,
    which involves coercive joinder of a state sovereign. In-
    deed, none of the cases identified by Gensetix examined the
    interplay between Rule 19(a) and state sovereign immun-
    ity. Accordingly, it is of no moment that the license agree-
    ment requires initiation of an infringement suit by
    Gensetix or cooperation by UT in any infringement suit.
    Although UT willingly entered into the license agreement,
    so too, did Gensetix. It agreed to terms expressly stating
    that UT was not waiving its sovereign immunity, and
    terms that allow UT to initiate a suit on behalf of Gensetix,
    but not the other way around. As we explain above, in the
    absence of a state voluntarily availing itself of federal court
    jurisdiction, or an express waiver of sovereign immunity,
    Rule 19(a) must yield to the state’s assertion of sovereign
    immunity.
    In sum, neither Supreme Court case law, nor the deci-
    sions of this circuit or our sister circuits, support Gensetix’s
    arguments that, absent waiver, a sovereign may be joined
    as an involuntary plaintiff under Rule 19(a). Accordingly,
    we affirm the district court’s conclusion that UT may not
    be joined as an involuntary plaintiff. 6
    6  While I may not speak for our splintered majority
    on this point, I have some sympathy for Judge Newman’s
    views. Unfortunately, absent abrogation of Florida Pre-
    paid Postsecondary Education Expense Board v. College
    Savings Bank, 
    527 U.S. 627
    (1999), which I suspect would
    be welcome by many, I remain of the view that involuntary
    joinder of UT as a plaintiff to this action is impermissible.
    Case: 19-1424     Document: 77       Page: 13     Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                   13
    B. The District Court Abused Its Discretion
    In Concluding That This Case Must Be
    Dismissed In UT’s Absence
    We next consider whether the district court properly
    concluded that this case cannot proceed in UT’s absence. A
    district court’s analysis under Rule 19(b) is a matter of re-
    gional circuit law. Univ. of Utah v. Max-Planck-Gesell-
    schaft zur Forderung der Wissenschaften E.V., 
    734 F.3d 1315
    , 1320 (Fed. Cir. 2013). The Fifth Circuit reviews a
    district court’s decision to dismiss a suit pursuant to the
    Rule 19(b) inquiry for abuse of discretion. Hood v. City of
    Memphis, 
    570 F.3d 625
    , 628 (5th Cir. 2009). “Determining
    whether [a suit should be dismissed in the absence of a re-
    quired party] is a highly-practical, fact-based endeavor,
    and . . . a district court will ordinarily be in a better position
    to make a Rule 19 decision than a circuit court would be.”
    Id. (internal citations
    omitted). 7 “A district court abuses
    its discretion if it: (1) relies on clearly erroneous factual
    findings; (2) relies on erroneous conclusions of law; or
    (3) misapplies the law to the facts.” In re Volkswagen of
    Am., Inc., 
    545 F.3d 304
    , 310 (5th Cir. 2008) (en banc)). And,
    “[a] district court would necessarily abuse its discretion if
    7    Gensetix submits that we should review this issue
    de novo and argues that the district court committed legal
    error by (1) assuming that UT was indispensable even be-
    fore it conducted its factor-by-factor analysis, and (2) fail-
    ing to consider the equities. Appellant’s Br. 16–24. We
    reject this attempt to manufacture legal error based on out-
    of-context statements from the district court’s opin-
    ion. Gensetix cannot deny that the district court did, in
    fact, conduct a factor-by-factor Rule 19(b) analysis. Con-
    trary to Gensetix’s arguments, moreover, the district court
    did not fail to consider the equities in its Rule 19(b) analy-
    sis. This analysis is properly reviewed under an abuse of
    discretion standard.
    Case: 19-1424    Document: 77      Page: 14     Filed: 07/24/2020
    14             GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    it based its ruling on an erroneous view of the law or on a
    clearly erroneous assessment of the evidence.” Highmark
    Inc. v. Allcare Health Mgmt. Sys., Inc., 
    572 U.S. 559
    ,
    564 n.2 (2014).
    Rule 19(b) provides that, where joinder of a required
    party is not feasible, “the court must determine whether,
    in equity and good conscience, the action should proceed
    among the existing parties or should be dismissed.” Fed.
    R. Civ. P. 19(b). This inquiry involves consideration of four
    factors: (1) the extent to which a judgment rendered might
    prejudice the missing required party or the existing par-
    ties; (2) the extent to which any prejudice could be lessened
    or avoided (3) whether a judgment rendered in the required
    party’s absence would be adequate; and (4) “whether the
    plaintiff would have an adequate remedy if the action were
    dismissed for nonjoinder.”
    Id. On appeal,
    Gensetix argues
    that the district court abused its discretion by failing to
    meaningfully analyze each of the Rule 19(b) factors. 8 As
    explained below, we agree.
    8   UT and Baylor argue that Gensetix waived many
    of its arguments regarding the court’s Rule 19(b) analysis.
    Under Fifth Circuit case law, “an argument is not waived
    on appeal if the argument on the issue before the district
    court was sufficient to permit the district court to rule on
    it.” In re Liljeberg Enters., Inc., 
    304 F.3d 410
    , 427 n.29 (5th
    Cir. 2002). Gensetix’s arguments to the district court were
    sufficient. It is true, moreover, that a party cannot waive
    objection to a court’s failure to apply the correct legal
    standard to the question presented. Myco Indus., Inc. v.
    BlephEx, LLC, 
    955 F.3d 1
    , 11 (Fed. Cir. 2020) (citing
    United States v. Ali, 
    508 F.3d 136
    , 144 n.9 (3d Cir. 2007),
    and Brown v. Smith, 
    551 F.3d 424
    , 428 n.2 (6th Cir. 2008)).
    Accordingly, we conclude that Gensetix did not waive any
    arguments regarding the Rule 19(b) inquiry.
    Case: 19-1424    Document: 77      Page: 15     Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                15
    The district court found that three out of the four
    Rule 19(b) factors weighed in favor of dismissing the case.
    As to the first factor—the extent to which a judgment ren-
    dered in UT’s absence might prejudice UT or the parties to
    the litigation—relying on our decision in A123 Systems,
    Inc. v. Hydro-Quebec, 
    626 F.3d 1213
    (Fed. Cir. 2010), the
    court found that “UT risks an invalidation of its patent
    without the opportunity to litigate.” Gensetix, 
    354 F. Supp. 3d
    at 764. It concluded that it “must give sufficient weight
    to the prejudice to UT, which is absent from this suit based
    on a claim of sovereign immunity.’’
    Id. (quoting A123,
     626 F.3d at 1221). Without any analysis of the second fac-
    tor, the court also found that it would not be able to lessen
    or avoid prejudice to UT.
    Id. (citing A123,
    626 F.3d
    at 1222 n.1). As to the third factor, the court found that a
    judgment rendered without UT would be inadequate.
    Id. It noted
    Baylor’s argument that there is a risk of multiple
    suits against Baylor on the same patents. But, it nonethe-
    less “decline[d] to determine whether UT would be judi-
    cially estopped from later filing suit against [Baylor] for the
    purposes of this Rule 19(b) analysis.”
    Id. Finally, as
    to the
    fourth factor—whether Gensetix would have an adequate
    remedy if the action were dismissed for nonjoinder—the
    court found it “seemingly” weighed in favor of Gen-
    setix. Regardless, the court “refused to effectuate a rescue”
    by joining UT, noting that, “[w]hile this result may be
    harsh, it is an inherent risk for anyone who chooses to con-
    tract with a sovereign entity.”
    Id. The parties
    argue at length about the facts applicable
    to each factor, but we need not delve into each argument to
    assess the appropriateness of the district court’s analysis.
    We conclude that the district court abused its discretion by
    collapsing the multi-factorial Rule 19(b) inquiry into one
    dispositive fact: UT’s status as a sovereign. For example,
    in evaluating the prejudice to UT, the district court relied
    on our decision in A123 and concluded that it must give
    weight to the fact that the sovereign risked losing rights in
    Case: 19-1424     Document: 77      Page: 16     Filed: 07/24/2020
    16              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    its patent without an opportunity to defend itself. Gen-
    setix, 
    354 F. Supp. 3d
    at 764. But in A123, we noted that
    the interests of the licensee and licensor were “overlap-
    ping” not “identical,” because the licensee had only a field-
    of-use license. 
    A123, 626 F.3d at 1221
    . We concluded that
    this left open the possibility of the licensee advancing ar-
    guments during litigation that served its own interests but
    not that of the absent licensor.
    Id. Here, as
    Gensetix cor-
    rectly points out, it has a license in every field, and, as such,
    the parties’ interests in the validity of the patents-in-suit
    are identical. Appellant’s Br. 27. The prejudice to UT is
    minimal, or at least substantially mitigated, because, un-
    like the licensee in A123, Gensetix will adequately protect
    UT’s interests in the validity of the patents-in-suit.
    Likewise, the court dismissed the lack of an adequate
    remedy for Gensetix resulting from UT’s nonjoinder—i.e.,
    the fourth Rule 19(b) factor—as simply “an inherent risk
    for anyone who chooses to contract with a sovereign entity.”
    Id. That may
    be true, but this fact is more relevant to join-
    der under Rule 19(a) than it is to the Rule 19(b) analysis.
    Rather than cede control, once again, to UT’s claim of sov-
    ereign immunity, the district court should have given
    weight to the fact that Gensetix is without recourse to as-
    sert its patent rights because UT cannot be feasibly joined.
    Accordingly, we conclude that the district court abused its
    discretion in giving overwhelming weight to UT’s sovereign
    status to the exclusion of all other facts.
    Pimentel, on which UT relies, does not compel a differ-
    ent conclusion. Pimentel involved an interpleader action
    commenced to determine ownership of property allegedly
    stolen by Ferdinand Marcos, the former President of the
    Philippines. In concluding that the action should not have
    proceeded in the Republic of Philippines’ absence, the Su-
    preme Court noted that a sovereign’s immunity from suit
    is a “privilege [that] is much diminished if an important
    and consequential ruling affecting the sovereign’s substan-
    tial interest is determined, or at least assumed, by a federal
    Case: 19-1424    Document: 77      Page: 17    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE               17
    court in the sovereign’s absence and over its objection.” Pi-
    
    mentel, 553 U.S. at 868
    (emphasis added). The Court ex-
    plained that, “where sovereign immunity is asserted, and
    the claims of the sovereign are not frivolous, dismissal of
    the action must be ordered where there is a potential for
    injury to the interests of the absent sovereign.”
    Id. at 867
     (emphasis added). This seemingly broad language is best
    understood, however, within the specific facts of Pimentel.
    First, the case dealt with foreign sovereign immunity, not
    state sovereign immunity, and the Court placed some
    weight on the “[c]omity and dignity interests” at play.
    Id. at 869.
    No comity concerns exist here. Second, and more
    importantly, there was no dispute in Pimentel that the ab-
    sence of the Philippines in the interpleader suit would re-
    sult in its interests going unprotected.
    Id. at 863–64.
    By
    contrast, here, Gensetix is fully able (and willing) to step
    into UT’s shoes and protect the absent sovereign’s interests
    in the validity of the patents-in-suit. Indeed, in the license
    agreement, UT required that it do so. Finally, in Pimentel,
    the claim was not extinguished for lack of an alternative
    forum, unlike here.
    In his dissent-in-part, Judge Taranto, respectfully,
    reads too much into Pimentel. We do not agree that the
    Court gave “controlling weight to the sovereign interest” in
    that case. In evaluating the first Rule 19(b) factor, the
    Court concluded that the district court and the Court of Ap-
    peals “gave insufficient weight to the likely prejudice to”
    the sovereign.
    Id. at 869.
    The Court nonetheless analyzed
    the remaining Rule 19(b) factors before concluding that the
    action must be dismissed. Rather than announcing a
    bright-line rule, the Court clarified that “Rule 19 cannot be
    applied in a vacuum, and it may require some preliminary
    assessment of the merits of certain claims.”
    Id. at 868.
    It
    also made clear that in conducting “the Rule 19(b) inquiry,
    a court must examine, to some extent, the claims presented
    and the interests likely to be asserted both by the joined
    parties and the absent entities or persons.”
    Id. (emphasis Case:
    19-1424    Document: 77      Page: 18     Filed: 07/24/2020
    18             GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    added). The deciding factor in Pimentel was the court giv-
    ing insufficient, rather than controlling, weight to the
    likely prejudice to the sovereign. 9 We conclude that a
    proper application of Pimentel mandates consideration of
    the claims presented and the interests asserted by UT,
    Gensetix, and Baylor—an analysis the district court failed
    to properly engage in.
    Beyond giving controlling weight to UT’s status as a
    sovereign in its analysis of several of the applicable factors,
    in concluding that a judgment rendered in UT’s absence
    would be inadequate, the district court also refused to
    properly analyze the third Rule 19(b) factor. In refusing to
    consider whether UT would be barred from filing suit
    against Baylor, such that there would be a risk of multiple
    suits, the court ignored its own express finding that, under
    the terms of the agreement, UT’s right to sue is secondary,
    and it cannot initiate a lawsuit against Baylor now that
    Gensetix has done so. Therefore, allowing the litigation to
    proceed in UT’s absence does not pose a substantial risk of
    multiple suits.
    9   We are likewise unpersuaded by that opinion’s ref-
    erence to decisions from two of our sister circuits in support
    of the assertion that a court must give “decisive weight” to
    a state’s sovereign interest in conducting this analysis. See
    Taranto Op. at 3–4 (citing, e.g., Kickapoo Tribe of Indians
    v. Babbitt, 
    43 F.3d 1491
    , 1498 (D.C. Cir. 1995) and Dine
    Citizens Against Ruining Our Env’t v. Bureau of Indian Af-
    fairs, 
    932 F.3d 843
    , 858 (9th Cir. 2019)). The cited cases
    either pre-date Pimentel or do not interpret it. And, these
    cases do not present a situation, where, like here, one of the
    parties to the litigation has an interest in the subject mat-
    ter of the litigation that is identical to the absent sover-
    eign’s interest, thereby mitigating the prejudice to the
    sovereign.
    Case: 19-1424    Document: 77      Page: 19    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE               19
    The proper analysis of the Rule 19(b) factors is far more
    nuanced than the district court’s. As to the prejudice to
    UT, the interests of UT and Gensetix are aligned. Despite
    UT’s sovereign status, given Gensetix’s identical interest
    in the validity of the patents-in-suit, any prejudice to UT is
    greatly reduced. There is also no risk of multiple suits be-
    cause, under the express terms of the parties’ agreement,
    UT may not sue Baylor once Gensetix has commenced liti-
    gation. And, as an exclusive licensee with less than all sub-
    stantial rights in the patents-in-suit, Gensetix cannot
    enforce its patent rights without the court allowing the suit
    to proceed in UT’s absence. Given this clear factual record,
    we conclude that it was an abuse of discretion to find that
    the suit may not proceed in UT’s absence. Accordingly, we
    reverse the district court on this point.
    III. CONCLUSION
    We have considered the parties’ remaining arguments
    and find them unpersuasive. For the foregoing reasons, we
    affirm-in-part, reverse-in-part, and remand for proceed-
    ings consistent with this opinion.
    AFFIRMED-IN-PART, REVERSED-IN-PART, AND
    REMANDED
    COSTS
    Each party to bear its own costs.
    Case: 19-1424   Document: 77      Page: 20   Filed: 07/24/2020
    United States Court of Appeals
    for the Federal Circuit
    ______________________
    GENSETIX, INC.,
    Plaintiff-Appellant
    v.
    THE BOARD OF REGENTS OF THE UNIVERSITY
    OF TEXAS SYSTEM,
    Plaintiff-Appellee
    v.
    BAYLOR COLLEGE OF MEDICINE, DIAKONOS
    RESEARCH LTD, WILLIAM K. DECKER,
    Defendants-Appellees
    ______________________
    2019-1424
    ______________________
    Appeal from the United States District Court for the
    Southern District of Texas in No. 4:17-cv-01025, Judge An-
    drew S. Hanen.
    ______________________
    NEWMAN, Circuit Judge, concurring in part, dissenting in
    part, concurring in the judgment.
    The panel majority holds that the Board of Regents of
    the University of Texas System (“the University” or “UT”)
    has Eleventh Amendment immunity that shields it from
    involuntary joinder in this infringement suit against Bay-
    lor College of Medicine and others. Respectfully, I disa-
    gree.
    Case: 19-1424    Document: 77     Page: 21    Filed: 07/24/2020
    2              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    The University is the assignee of the patents at issue,
    of which William K. Decker et al. are inventors. The Uni-
    versity licensed the patents to Gensetix, Inc. for commer-
    cial development, with significant payments to the
    University. The “Patent And Technology License Agree-
    ment” grants Gensetix the exclusive right to make, use,
    and sell the patented subject matter for the life of the pa-
    tents, and requires Gensetix to enforce the patents against
    any infringer. However, when Gensetix sought cooperation
    in this infringement suit, the University refused to join or
    be joined as a party, and invoked the Eleventh Amendment
    to bar involuntary joinder, thus preventing enforcement of
    the patents. The district court deemed the University to be
    a necessary party, and dismissed Gensetix’s infringement
    suit. 1
    I respectfully dissent from the court’s holding that the
    University has Eleventh Amendment immunity from join-
    der in this litigation. However, this infringement suit may
    proceed without the University as a party, in conformity
    with Federal Rule of Civil Procedure 19(b); thus I concur in
    the court’s judgment.
    The Eleventh Amendment does not insulate a
    State from its contractual obligations
    Just as the State must pay its bills, it also must comply
    with its contracts. The purpose of the Eleventh Amend-
    ment is to shield a State’s sovereign functions of govern-
    ance from judicial oversight in federal courts. See William
    A. Fletcher, The Eleventh Amendment: Unfinished Busi-
    ness, 75 Notre Dame L. Rev. 843, 854 (2000). When a State
    agency enters into commercial transactions, it is subject to
    the rules of commerce. As Justice Breyer explained in Col-
    lege Savings Bank v. Florida Prepaid Postsecondary
    1   Gensetix, Inc. v. Baylor Coll. of Med., 
    354 F. Supp. 3d
    759 (S.D. Tex. 2018) (“Dist. Ct. Op.”).
    Case: 19-1424    Document: 77      Page: 22    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                3
    Education Expense Board, 
    527 U.S. 666
    (1999): “When a
    State engages in ordinary commercial ventures, it acts like
    a private person, outside the area of its ‘core’ responsibili-
    ties, and in a way unlikely to prove essential to the fulfill-
    ment of a basic governmental obligation.”
    Id. at 694
     (Breyer, J., dissenting).
    The Eleventh Amendment is not an authorization
    whereby State agencies may violate their commercial and
    contractual obligations. Its purpose is not to absolutely
    “prevent states from being compelled to litigate,” as the dis-
    trict court stated. Dist. Ct. Op. at 766 (internal quotation
    marks omitted). The Supreme Court expressed this view
    in Ex parte Young, 
    209 U.S. 123
    (1908), holding that even
    if the State is immune from suit on a particular issue, its
    officials may not be immune.
    Id. at 167.
    As a recent illus-
    tration, in Pennington Seed, Inc. v. Produce Exchange No.
    299, 
    457 F.3d 1334
    (Fed. Cir. 2006), this court explained
    that although the University of Arkansas may assert Elev-
    enth Amendment immunity from suit for patent infringe-
    ment, that University’s officials can be sued.
    Id. at 1342.
         Here, the University of Texas obtained United States
    patents on inventions of the University’s scientists, and en-
    tered into an exclusive License Agreement with Gensetix
    for development and commercialization. 2 Paragraph 7.1 of
    the License Agreement provides that Gensetix “must en-
    force any patent exclusively licensed hereunder against in-
    fringement by third parties,” and that if Gensetix does not
    do so within 6 months of learning of infringement, the Uni-
    versity has the right to sue the infringer(s) and retain any
    2    “Section 3.1 of the License Agreement states that
    Gensetix has the ‘exclusive’ right to manufacture, use, im-
    port, and sell the licensed product within the ‘licensed ter-
    ritory’ (L.A. § 2.5: ‘licensed territory means worldwide’) for
    use within the ‘licensed field’ (L.A. § 2.2: ‘licensed field
    means all fields of use.’).” Dist. Ct. Op. at 770.
    Case: 19-1424    Document: 77      Page: 23    Filed: 07/24/2020
    4              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    recovery. License Agreement at 13–14. And Paragraph 7.2
    of the License Agreement states that in any infringement
    action “the parties agree to cooperate fully with each
    other.” License Agreement at 14.
    The University now refuses such cooperation, by refus-
    ing to be named as a party to the suit, thereby preventing
    enforcement of the patents—although the License Agree-
    ment requires Gensetix to enforce the patents. The Uni-
    versity not only violates its agreement to “cooperate fully,”
    but also deprives its licensee of the agreed upon exclusivity.
    The University achieves this result by invoking the Elev-
    enth Amendment.
    This is not a matter of shielding the State from the “in-
    dignity” of judicial process, as in Seminole Tribe of Florida
    v. Florida, 
    517 U.S. 44
    , 58 (1996). When a State enters into
    commerce, it accedes to the rules of commerce. See White
    v. Massachusetts Council of Const. Employers, Inc., 
    460 U.S. 204
    , 207 (1983) (“There is no indication of a constitu-
    tional plan to limit the ability of the States themselves to
    operate freely in the free market.” (quoting Reeves, Inc. v.
    Stake, 
    447 U.S. 429
    , 436–47 (1980))).
    I do not share the majority’s conclusion that the Elev-
    enth Amendment shields the University from compliance
    with its contractual obligation to “cooperate fully” with its
    exclusive licensee, Gensetix, in enforcing these patents
    against infringers. 3
    3   The Supreme Court recently reaffirmed “a princi-
    ple as old as the Nation itself: The Government should
    honor its obligations. Soon after ratification, Alexander
    Hamilton stressed this insight as a cornerstone of fiscal
    policy. ‘States,’ he wrote, ‘who observe their engage-
    ments . . . are respected and trusted: while the reverse is
    the fate of those . . . who pursue an opposite conduct.’ Cen-
    turies later, this Court’s case law still concurs.” Maine
    Case: 19-1424    Document: 77      Page: 24    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                 5
    This infringement suit may proceed under
    Rule 19(b) without joinder of the University
    The district court held that the University, as patent
    assignee, is a necessary party to this infringement suit
    brought by its exclusive licensee. If the assignee is indeed
    a necessary party, in most situations it can be joined as a
    voluntary or involuntary party. However, if joinder is not
    available, the question is whether it is an indispensable
    party. Dainippon Screen Mfg. Co. v. CFMT, Inc., 
    142 F.3d 1266
    , 1272 (Fed. Cir. 1998).
    The question of whether and when a licensee may sue
    infringers in its own name was elaborated in Waterman v.
    Mackenzie, 
    138 U.S. 252
    (1891); the Court stated:
    The patentee or his assigns may, by instrument in
    writing, assign, grant, and convey, either (1) the
    whole patent, comprising the exclusive right to
    make, use, and vend the invention throughout the
    United States; or (2) an undivided part or share of
    that exclusive right; or (3) the exclusive right under
    the patent within and throughout a specified part
    of the United States.
    Id. § 4898.
    A transfer of ei-
    ther of these three kinds of interests is an assign-
    ment, properly speaking, and vests in the assignee
    a title in so much of the patent itself, with a right
    to sue infringers. In the second case, jointly with
    the assignor. In the first and third cases, in the
    name of the assignee alone.
    Id. at 255.
    Following the Court’s holding in Waterman, a
    conveying of the “whole patent, comprising the exclusive
    Community Health Options v. United States, 
    140 S. Ct. 1308
    , 1331 (2020) (ellipses in original) (quoting Report Rel-
    ative to a Provision for the Support of Public Credit (Jan.
    9, 1790), in 6 Papers of Alexander Hamilton 68 (H. Syrett
    & J. Cooke eds. 1962) (internal citations omitted)).
    Case: 19-1424    Document: 77      Page: 25     Filed: 07/24/2020
    6              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    right to make, use, and vend the invention throughout the
    United States” is tantamount to an assignment, and vests
    in the assignee “a right to sue infringers . . . in the name of
    the assignee alone.”
    Id. However, the
    district court relied
    on Alfred E. Mann Found. for Sci. Research v. Cochlear
    Corp., 
    604 F.3d 1354
    (Fed. Cir. 2010) to support holding
    that the University’s default right to sue infringers if Gen-
    setix did not do so, was a right so substantial that it de-
    feated Gensetix’s right to sue as exclusive licensee. Dist.
    Ct. Op. at 769–71.
    Here, the issue is resolved not only by Federal Rule
    19(b), but also by legal and equitable theories of property
    rights, such as the constructive trust described in Inde-
    pendent Wireless Telegraph Co. v. Radio Corporation of
    America, 
    269 U.S. 459
    , 468 (1926) (patent owner holds title
    in trust for exclusive licensee); or determining whether the
    license is “by way of mortgage and liable to be defeated by
    non-performance of a condition subsequent,” as described
    in Vaupel Textilmaschinen KG v. Meccanica Euro Italia
    SPA, 
    944 F.2d 870
    , 875 (Fed. Cir. 1991) (holding that “the
    termination provisions in the agreements were entirely
    consistent with an assignment.”).
    Applying the principles of precedent to the Gensetix-
    University License Agreement, the default provision for su-
    ing infringers is consistent with the assignment of exclu-
    sive patent rights, whereby Gensetix may sue infringers in
    its own name when, as here, the University declines to join
    or be joined.
    I join the court’s ruling that this litigation may proceed
    without the University as a party, and concur in the appli-
    cation of Federal Rule 19(b).
    Case: 19-1424    Document: 77      Page: 26    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                7
    The University’s rights of scientific publica-
    tion, research, and teaching are not patent
    rights
    In the district court, Baylor had moved for dismissal on
    the ground that “the only allegations of patent infringe-
    ment in the Complaint were allegations of research activi-
    ties.” University Br. 5 n.1. The district court did not decide
    this motion, instead dismissing the action on the Eleventh
    Amendment ground.
    The License Agreement states that the University has
    the right to “[p]ublish the general scientific findings from
    research,” to use the subject matter for “academically-re-
    lated purposes” such as “research, teaching, [and] patient
    care,” and to transfer to “academic or research institutions
    for non-commercial research use.” License Agreement at 5
    (¶¶ 3.1(a), (b), (c)). The scientific/technologic information
    in patents is part of the balance in the Constitution’s pro-
    vision “To promote the Progress of Science and useful
    Arts,” Art. I, § 8, cl. 8. As explained by Justice Story in
    Sawin v. Guild, 
    21 F. Cas. 554
    , 555 (C.C.D. Mass. 1813),
    this balance distinguishes “the making with an intent to
    use for profit, and not for the mere purpose of philosophical
    experiment, or to ascertain the verity and exactness of the
    specification.” This principle has supported centuries of in-
    novation.
    The License Agreement’s acknowledgement of scien-
    tific knowledge is not a reservation of patent rights, and
    was inappropriately held by the district court to comprise
    substantial retained patent rights and thus to support
    Eleventh Amendment immunity.
    CONCLUSION
    Although I do not agree with the court’s holding that
    the University has Eleventh Amendment immunity from
    participation in this litigation, I do agree that this action
    may proceed in the absence of the University as a party.
    Case: 19-1424    Document: 77    Page: 27    Filed: 07/24/2020
    8              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    Thus I join in holding that this infringement suit may pro-
    ceed without joinder of the University, and in remanding
    for further proceedings.
    Case: 19-1424   Document: 77      Page: 28   Filed: 07/24/2020
    United States Court of Appeals
    for the Federal Circuit
    ______________________
    GENSETIX, INC.,
    Plaintiff-Appellant
    v.
    THE BOARD OF REGENTS OF THE UNIVERSITY
    OF TEXAS SYSTEM,
    Plaintiff-Appellee
    v.
    BAYLOR COLLEGE OF MEDICINE, DIAKONOS
    RESEARCH LTD, WILLIAM K. DECKER,
    Defendants-Appellees
    ______________________
    2019-1424
    ______________________
    Appeal from the United States District Court for the
    Southern District of Texas in No. 4:17-cv-01025, Judge An-
    drew S. Hanen.
    ______________________
    TARANTO, Circuit Judge, concurring in part and dissenting
    in part.
    I join Parts I and II-A of Judge O’Malley’s opinion
    except for footnote 6. Those portions of the opinion
    conclude that the constitutionally preserved protection of
    state sovereign immunity bars a coerced joinder of the
    University of Texas (UT), which is an arm of the State of
    Case: 19-1424    Document: 77       Page: 29    Filed: 07/24/2020
    2              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    Texas, as an involuntary plaintiff in this federal action,
    which Gensetix, Inc., as UT’s exclusive licensee, initiated
    to assert infringement of UT-owned patents. I agree that
    joinder of UT under Federal Rule of Civil Procedure 19(a),
    even though UT is a “required” party under that provision,
    would improperly subject UT “to the coercive process of
    judicial tribunals at the instance of private parties.”
    Seminole Tribe of Florida v. Florida, 
    517 U.S. 44
    , 58 (1996);
    see Franchise Tax Board of California v. Hyatt, 
    139 S. Ct. 1485
    , 1497 (2019).
    I part company with Judge O’Malley’s opinion in its
    conclusion, in Part II-B, that the district court erred in
    ruling that the infringement action should not proceed
    under Rule 19(b) without the presence of required-party
    UT. For that reason, I dissent from the majority’s reversal
    of the district court’s dismissal of the action. The Supreme
    Court’s decision in Republic of Philippines v. Pimentel, 
    553 U.S. 851
    (2008), explains that when a sovereign entity is a
    required party under Rule 19(a), is protected against
    joinder by sovereign immunity, and makes a non-frivolous
    assertion that it will be prejudiced by a suit proceeding in
    its absence, a district court is generally obligated to dismiss
    the suit under Rule 19(b). Because UT made such an
    assertion, I see no abuse of discretion in the district court’s
    dismissal of this action, which I would affirm.
    I
    In Pimentel, the Supreme Court considered whether a
    federal-court action may proceed, under Rule 19(b),
    without the presence of a sovereign entity that was a
    “required” party under Rule 19(a) but that could not be
    joined because of sovereign 
    immunity. 553 U.S. at 863
    .
    The Court recognized that it “ha[d] not considered a case
    posing the precise question presented,” but it noted that
    there were “some authorities involving the intersection of
    joinder and the governmental immunity of the United
    States.”
    Id. at 866.
    The “analysis of the joinder issue in
    Case: 19-1424     Document: 77      Page: 30    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                  3
    those cases”—Mine Safety Appliances Co. v. Forrestal, 
    326 U.S. 371
    (1945) and Minnesota v. United States, 
    305 U.S. 382
    (1939)—“was somewhat perfunctory,” the Court wrote,
    “but the holdings were clear: A case may not proceed when
    a required-entity sovereign is not amenable to suit.”
    
    Pimentel, 553 U.S. at 866
    –67 (emphasis added).
    Based on those holdings, the Court in Pimentel stated
    its conclusion in the following bright-line-rule terms:
    “where sovereign immunity is asserted, and the claims of
    the sovereign are not frivolous, dismissal of the action must
    be ordered where there is a potential for injury to the
    interests of the absent sovereign.”
    Id. at 867
    (emphasis
    added). The Court stated that rule, as it stated its
    summary of the earlier holdings, in terms of an immunity-
    protected “sovereign” generally, not only a foreign
    sovereign or the United States. Moreover, the Court’s
    statement that “dismissal of the action must be ordered”
    lacks a qualifier allowing for other Rule 19(b) factors to
    outweigh the protection of a sovereign’s non-frivolous
    interest. Although the Court discussed such other factors,
    the discussion gives controlling weight to the sovereign
    interest.
    Id. at 869–72.
         Consistent with Pimentel, at least two federal courts of
    appeals have mandated, or at least approved, giving
    decisive weight under Rule 19(b) to avoiding impairment of
    a sovereign interest in the contexts of sovereign immunity
    of States and Indian tribes. In a case involving state
    sovereign immunity, the D.C. Circuit concluded, before
    Pimentel, that “[w]hile Rule 19(b) sets forth four non-
    exclusive factors . . . ‘there is very little room for balancing
    of other factors’ set out in Rule 19(b) where a necessary
    party under Rule 19(a) is immune from suit because
    immunity may be viewed as one of those interests
    ‘compelling by themselves.’” Kickapoo Tribe of Indians v.
    Babbitt, 
    43 F.3d 1491
    , 1496 (D.C. Cir. 1995) (quoting
    Wichita & Affiliated Tribes of Oklahoma v. Hodel, 
    788 F.2d 765
    , 777 n.13 (D.C. Cir. 1986)). In a case involving tribal
    Case: 19-1424    Document: 77       Page: 31   Filed: 07/24/2020
    4              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    sovereign immunity, the Ninth Circuit observed, before
    Pimentel, that “some courts have held that sovereign
    immunity forecloses in favor of tribes the entire balancing
    process under Rule 19(b).” Am. Greyhound Racing, Inc. v.
    Hull, 
    305 F.3d 1015
    , 1025 (9th Cir. 2002). More recently,
    the Ninth Circuit reiterated that “there is a ‘wall of circuit
    authority’ in favor of dismissing actions in which a
    necessary party cannot be joined due to tribal sovereign
    immunity—‘virtually all the cases to consider the question
    appear to dismiss under Rule 19, regardless of whether [an
    alternate] remedy is available, if the absent parties are
    Indian tribes invested with sovereign immunity.’” Dine
    Citizens Against Ruining Our Environment v. Bureau of
    Indian Affairs, 
    932 F.3d 843
    , 857 (9th Cir. 2019) (citing
    White v. University of California, 
    765 F.3d 1010
    , 1028 (9th
    Cir. 2014)).
    I see neither authority nor a persuasive basis for
    excluding state sovereign immunity from the Pimentel rule,
    which, as noted, the Supreme Court stated in terms
    covering immunity-protected sovereigns generally. In any
    event, and what suffices for the present case, I see no
    authority or good reason for prohibiting a trial court from
    giving controlling effect to the protection of a state
    sovereign’s non-frivolous interest from impairment by
    litigation in its absence when the state sovereign is a
    required party under Rule 19(a).
    II
    Whether a suit can proceed without an absent,
    required party is a “matter of regional circuit law.”
    University of Utah v. Max-Planck-Gesellschaft zur
    Forderung der Wissenschaften E.V., 
    734 F.3d 1315
    , 1320
    (Fed. Cir. 2013). The Fifth Circuit reviews such a
    determination for an abuse of discretion. See Acevedo v.
    Allsup’s Convenience Stores, Inc., 
    600 F.3d 516
    , 520 (5th
    Cir. 2010) (“Rulings on the joinder of parties are reviewed
    for abuse of discretion.”). A district court “abuses its
    Case: 19-1424    Document: 77      Page: 32     Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE                 5
    discretion when it makes ‘a clear error of judgment in
    weighing relevant factors or in basing its decision on an
    error of law or on clearly erroneous factual findings.’”
    Thermolife International LLC v. GNC Corporation, 
    922 F.3d 1347
    , 1356 (Fed. Cir. 2019) (citing Bayer CropScience
    AG v. Dow AgroSciences LLC, 
    851 F.3d 1302
    , 1306 (Fed.
    Cir. 2017)).
    Here, it suffices, to find no abuse of discretion, that UT
    has made a non-frivolous claim that its interests as patent
    owner could easily be harmed—by, e.g., narrow-scope
    rulings or invalidation—if the suit proceeds in its absence.
    See Brief for University of Texas at 32–33 (“UT would risk
    an invalidation of its patents without the opportunity to
    litigate”);
    id. at 34
    (“In its filing below, UT pointed out the
    invalidation risk as well as the risk that the ‘construction
    of those claims [] will impact the value of the patents.’”
    (citing J.A. 628)).
    It is not disputed on appeal that UT retained
    substantial rights in the asserted patents, as the district
    court concluded. Gensetix, Inc. v. Baylor College of
    Medicine, 
    354 F. Supp. 3d 759
    , 768–71 (S.D. Tex. 2018).
    The district court noted that “UT retains a broad right to
    sue and control litigation”; that UT “retained the right to
    publish general findings, use licensed subject matter for
    research, teaching, or other academic purposes, and
    transfer rights to other research institutions for non-
    commercial research use”; and that Gensetix’s rights “are
    subject to termination provisions.”
    Id. at 770–71.
     Moreover, the district court observed, “UT and Gensetix
    share a financial interest in litigation because if Gensetix
    initiates an infringement suit, both entities are entitled to
    recovery.”
    Id. at 771.
    UT thus has a substantial interest
    in maintaining the value of the patents.
    It is far from frivolous to assert that UT’s interest could
    be impaired by an invalidity ruling or a narrow claim
    construction. The doctrines of claim and issue preclusion
    Case: 19-1424    Document: 77      Page: 33    Filed: 07/24/2020
    6              GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE
    might prevent UT from relitigating such adverse rulings
    made in this suit, given that the UT-Gensetix license
    agreement designates Gensetix as UT’s representative in
    infringement litigation, J.A. 314–15. See Restatement
    (Second) of Judgments § 41 (a “person who is not a party to
    an action but who is represented by a party is bound by and
    entitled to the benefits of judgment as though he were a
    party”). In any event, a ruling that the patents’ claims are
    invalid or are narrow in scope would be harmful at least as
    adverse precedent. In A123 Systems, Inc. v. Hydro-Quebec,
    another case involving UT, we relied on Pimentel and
    affirmed the district court’s conclusion that “were it to
    reinstate the action and declare the patents invalid, UT
    would lose all rights in its patents despite the fact that it
    had no opportunity to defend its interests in the litigation.”
    
    626 F.3d 1213
    , 1221 (Fed. Cir. 2010). Accordingly, we were
    obligated to “give sufficient weight to the prejudice to UT.”
    Id. The same
    is true here.
    This conclusion suffices to affirm the district court’s
    dismissal of the present action as not an abuse of
    discretion. I have no reason to doubt that this result leaves
    Gensetix without any forum to press the infringement
    claims it has presented in this action. (Whether Gensetix
    may sue UT for breach of contract is a separate matter.)
    But in Pimentel, the Court expressly noted that
    “[d]ismissal under Rule 19(b) will mean, in some instances,
    that plaintiffs will be left without a forum for definitive
    resolution of their claims” and that such a “result is
    contemplated under the doctrine of foreign sovereign
    
    immunity.” 553 U.S. at 872
    ; see also Wichita & Affiliated
    
    Tribes, 788 F.2d at 777
    (stating that “dismissing an action
    where there is no alternative forum” is “less troublesome”
    when dismissal is compelled by sovereign immunity
    because the loss of forum results not from “some procedural
    defect such as venue” but from “the fact that society has
    consciously opted to shield [sovereigns] from suit without
    . . . consent”). More generally, the Supreme Court’s state
    Case: 19-1424    Document: 77     Page: 34    Filed: 07/24/2020
    GENSETIX, INC. v. BAYLOR COLLEGE OF MEDICINE               7
    sovereign immunity jurisprudence contemplates that
    patent owners may be left without a remedy when States
    are involved. See Allen v. Cooper, 
    140 S. Ct. 994
    , 1001
    (2020).
    Because UT made a non-frivolous assertion that it will
    be harmed if this suit proceeds, I would hold that the
    district court did not abuse its discretion by dismissing the
    suit. I respectfully dissent from the judgment of the court
    reversing the district court’s decision.
    

Document Info

Docket Number: 19-1424

Filed Date: 7/24/2020

Precedential Status: Precedential

Modified Date: 7/24/2020

Authorities (31)

Oklahoma Ex Rel. Edmondson v. Magnolia Marine Transport Co. , 359 F.3d 1237 ( 2004 )

California v. Atlantic Richfield Co. (In Re Methyl Tertiary ... , 488 F.3d 112 ( 2007 )

Acevedo v. Allsup's Convenience Stores, Inc. , 600 F.3d 516 ( 2010 )

United States v. Ali , 508 F.3d 136 ( 2007 )

Lifemark Hospitals, Inc. v. Liljeberg Enterprises, Inc. (In ... , 304 F.3d 410 ( 2002 )

Hood Ex Rel. Mississippi v. City of Memphis, Tenn. , 570 F.3d 625 ( 2009 )

american-greyhound-racing-inc-a-delaware-corporation-western-racing , 305 F.3d 1015 ( 2002 )

Kickapoo Tribe of Indians of the Kickapoo Reservation in ... , 43 F.3d 1491 ( 1995 )

Vaupel Textilmaschinen Kg and Vaupel North America v. ... , 944 F.2d 870 ( 1991 )

Abbott Laboratories v. Diamedix Corporation, Proposed ... , 47 F.3d 1128 ( 1995 )

Dainippon Screen Manufacturing Co., Ltd. And Dns ... , 142 F.3d 1266 ( 1998 )

The Regents of the University of New Mexico v. Galen D. ... , 321 F.3d 1111 ( 2003 )

Alfred E. Mann Foundation for Scientific Research v. ... , 604 F.3d 1354 ( 2010 )

wichita-and-affiliated-tribes-of-oklahoma-v-donald-p-hodel-secretary , 788 F.2d 765 ( 1986 )

Independent Wireless Telegraph Co. v. Radio Corp. of America , 46 S. Ct. 166 ( 1926 )

Gunter v. Atlantic Coast Line Railroad , 26 S. Ct. 252 ( 1906 )

Ex Parte Young , 28 S. Ct. 441 ( 1908 )

Reeves, Inc. v. Stake , 100 S. Ct. 2271 ( 1980 )

A123 Systems, Inc. v. Hydro-Quebec , 626 F.3d 1213 ( 2010 )

The Regents of the University of California v. Eli Lilly ... , 119 F.3d 1559 ( 1997 )

View All Authorities »